P11-4 vs Ibutamoren
Head-to-head comparison of P11-4 (Self-assembling peptide P11-4 (Ac-QQRFEWEFEQQ-NH2)) and Ibutamoren (Ibutamoren mesylate (MK-677)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | P11-4 | Ibutamoren |
|---|---|---|
| Category | Dental & Oral | Growth Hormone |
| Full Name | Self-assembling peptide P11-4 (Ac-QQRFEWEFEQQ-NH2) | Ibutamoren mesylate (MK-677) |
| Molecular Weight | 1466 Da | N/A |
| Half-Life | local activity for hours; peptide degraded over time | about 24 hours |
| Amino Acids | 11 | N/A |
| Typical Dose | 0.5-5 mg per lesion | 10-25 mg/day |
| Route | Topical/Intraoral | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 40 | 180 |
| Research Status | Clinical | Clinical |
P11-4 Benefits
- ✓enamel remineralization
- ✓early caries arrest
- ✓biomimetic scaffold formation
- ✓minimally invasive repair
Ibutamoren Benefits
- ✓raises GH/IGF-1
- ✓increases appetite
- ✓supports lean mass retention
- ✓oral non-peptide secretagogue
P11-4 Dosing
topical application to cleaned lesion|single-visit in-office application|repeat at follow-up if indicated
Ibutamoren Dosing
10-25 mg orally once daily|take consistently at the same time each day|monitor fasting glucose and edema in longer studies
P11-4 Side Effects
- ⚠transient tooth sensitivity
- ⚠local irritation
- ⚠taste disturbance
Ibutamoren Side Effects
- ⚠increased appetite
- ⚠water retention/edema
- ⚠somnolence or lethargy
Research Overview
P11-4
P11-4 has been studied for its ability to penetrate initial carious lesions and self-assemble into a fibrillar matrix that nucleates hydroxyapatite. Human and preclinical studies support its role in non-invasive enamel repair.
Ibutamoren
Clinical studies show oral ibutamoren reliably elevates GH and IGF-1 over 24 hours with once-daily dosing. Body composition and appetite effects vary by population, and development has been limited by metabolic side effects.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.